Keywords: Soft tissue sarcoma, Oncologists views, USA, Europe, Decision Resources, Ziopharm, Zymaphos, Eisai, Halaven, Pfizer, Xalkori, Threshold, TH-302, Ifosamide
US and European oncologists see novel chemotherapies as best hope for soft tissue sarcoma
Article | 30 January 2013
Although interviewed oncologists in the USA and Europe would like to see a future of personalized medicine targeting different soft ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
